drugset / Trial / NCT01863251

Atomoxetine for ATS and Opioid Dependence During Buprenorphine Maintenance Treatment in Malaysia

NCT01863251

Phase 2 Completed 90 enrolled Yale University
RandomizedFactorialQuadruple-blindTreatment

Summary

To evaluate the tolerability, acceptability and potential effect size of the efficacy of 4 months of atomoxetine treatment for patients with co-occurring ATS and heroin dependence (COATS) receiving buprenorphine maintenance treatment (BMT) and educational drug and HIV risk reduction counseling (EDRC).

Timeline

Start
2013-05
Primary completion
2014-08
Completion
2014-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified 80 mg
Subject Atomoxetine Other / unclassified 120 mg

Indications